BB&T Securities LLC boosted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,760 shares of the biopharmaceutical company’s stock after purchasing an additional 227 shares during the quarter. BB&T Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $4,765,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in REGN. Bank of Montreal Can lifted its stake in shares of Regeneron Pharmaceuticals by 27.5% in the third quarter. Bank of Montreal Can now owns 55,397 shares of the biopharmaceutical company’s stock valued at $22,383,000 after buying an additional 11,943 shares in the last quarter. First Hawaiian Bank bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $1,460,000. Nisa Investment Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 16.7% in the third quarter. Nisa Investment Advisors LLC now owns 21,642 shares of the biopharmaceutical company’s stock valued at $8,744,000 after buying an additional 3,098 shares in the last quarter. Essex Investment Management Co. LLC lifted its stake in shares of Regeneron Pharmaceuticals by 55.6% in the third quarter. Essex Investment Management Co. LLC now owns 12,613 shares of the biopharmaceutical company’s stock valued at $5,096,000 after buying an additional 4,509 shares in the last quarter. Finally, BB&T Corp lifted its stake in shares of Regeneron Pharmaceuticals by 11.1% in the third quarter. BB&T Corp now owns 16,655 shares of the biopharmaceutical company’s stock valued at $6,729,000 after buying an additional 1,665 shares in the last quarter. 73.18% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Oppenheimer raised their price target on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a research report on Thursday, February 7th. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals to $412.00 and gave the company a “market perform” rating in a research report on Thursday, February 7th. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 7th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $441.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $408.82.

Shares of REGN stock opened at $408.51 on Tuesday. The stock has a market capitalization of $44.03 billion, a price-to-earnings ratio of 20.63, a P/E/G ratio of 1.62 and a beta of 1.27. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $431.32.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, topping the consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The company’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.23 earnings per share. Research analysts predict that Regeneron Pharmaceuticals Inc will post 19.36 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, December 20th. The shares were sold at an average price of $358.97, for a total value of $663,376.56. Following the sale, the vice president now owns 9,871 shares of the company’s stock, valued at $3,543,392.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 1,791 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at approximately $5,786,740. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,645 shares of company stock worth $1,399,980. Insiders own 12.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BB&T Securities LLC Boosts Holdings in Regeneron Pharmaceuticals Inc (REGN)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2019/02/12/bbt-securities-llc-boosts-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Cash Flow

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.